ID
15543
Beschrijving
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Please document clinically significant findings as Adverse Events. Clinical Significance is defined as any variation in physical findings that has medical relevance and may result in an alteration in medical care. Safety Blood and Urine Examinations: Please document the results for Serum Creatinine, Platelets and TSH on CRF-Pages "Safety Laboratory Assessments". Part: Relapse Evaluation Visit No. 2
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Trefwoorden
Versies (1)
- 02-06-16 02-06-16 -
Geüploaded op
2 juni 2016
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Relapse Evaluation Visit No. 2 Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
C0449438 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0278454 (UMLS CUI [1,2])
C0022417 (UMLS CUI [1,3])
C0022417 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,2])
C1705848 (UMLS CUI [1,3])